Shire and AbbVie Discuss Possible Deal - - BioPharm International

ADVERTISEMENT

Shire and AbbVie Discuss Possible Deal


In a July 14 statement, Shire reported that the company had requested and received a revised proposal from AbbVie on July 13 for cash and AbbVie shares, with an indicative value of 53.20 British pounds per Shire share, based on share prices of July 11.

Under the revised proposal, Shire shareholders would own approximately 25% of the combined new AbbVie. The new proposal is valued at $53 billion (31 billion pounds) by Reuters.

“The Board of Shire has indicated to AbbVie that it would be willing to recommend an offer at the level of the Revised Proposal to Shire shareholders subject to satisfactory resolution of the other terms of the offer. Accordingly, the Board is in detailed discussions with AbbVie in relation to these terms,” the statement reports.

Shire reports that the revised proposal is subject to the pre-conditions set by AbbVie on July 8, 2014 including due diligence and the recommendation of the Board of Shire and warned that “There can be no certainty that any firm offer will be made.”

Sources:
Shire
Reuters

blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

Baxter Initiates Voluntary Recall of Potassium Chloride Injection
September 17, 2014
PDA Announces Technical Report on Drug Shortages
September 9, 2014
European Commission Approves RoACTEMRA for Treatment of RA
September 9, 2014
FDA Releases Guidance Electronic Submission of Lot Distribution Reports
September 5, 2014
Infinity and AbbVie Collaborate to Develop Oncology Drug
September 5, 2014
Author Guidelines

Click here